Rxo (RXO) EBITDA Margin (2021 - 2026)

Rxo (RXO) has reported EBITDA Margin for 6 consecutive years, with 0.06% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA Margin changed N/A year-over-year to 0.06%; the trailing twelve-month figure through Jun 2026 stood at 1.25% (up 8.0% YoY), and the FY2025 full-year result was 1.38%, down 15.0% from the prior year.
• EBITDA Margin advanced to 0.06% in Q2 2026 per RXO's latest filing, from 1.96% in the prior quarter.
• Across five years, EBITDA Margin topped out at 4.73% in Q2 2022 and bottomed at 2.86% in Q4 2025.
• Historically, EBITDA Margin has averaged 0.11% across 5 years, with a median of 0.02% in 2026.
• The sharpest annual moves came in 2022 and 2023: EBITDA Margin tumbled 423 bps in 2022, then jumped 152 bps in 2023.
• Over 5 years, EBITDA Margin stood at 0.09% in 2022, then surged by 1703 bps to 1.43% in 2023, then sank by 201 bps to 1.44% in 2024, then plunged by 99 bps to 2.86% in 2025, then soared by 102 bps to 0.06% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 0.06%, 1.96%, and 2.86% for Q2 2026, Q1 2026, and Q4 2025 respectively.